RLMD Relmada Therapeutics Inc

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.

Conference Call and Webcast Information:

  • Date: Thursday, November 13, 2025 at 4:30 PM ET
  • Participant Dial-in (US): 1-877-407-0792
  • Participant Dial-in (International): 1-201-689-8263
  • Webcast Access:

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit 

Investor Contact:

Brian Ritchie

LifeSci Advisors

Media Inquiries:

Corporate Communications



EN
07/11/2025

Underlying

RLMDRelmada Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relmada Therapeutics Inc

 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and ...

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in the adjuvant setting; Studies expected to begin H1 2026 Completed $100M underwritten offering of c...

7h / 40m 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on...

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, Nove...

November 7, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Of...

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,315,000 shares of common stock. The share...

November 4, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Regist...

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in intermediate-risk NMIBC. FDA Feedback also confirms no additional non-clinical studies are required. 9-month follow-up for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cance...

November 4, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max K...

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous sy...

October 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch